|Year : 2008 | Volume
| Issue : 5 | Page : 436-446
Therapeutic trials for systemic sclerosis: An update
Kabir Sardana, VK Garg
Department of Dermatology, Maulana Azad Medical College and Lok Nayak Hospital, Delhi, India
466, Sector 28, Noida 201 303, UP
Source of Support: None, Conflict of Interest: None
The pathogenesis of systemic sclerosis (SSc) is complex, and the final story is yet to be elucidated. The clinical heterogeneity of the disease, its various autoimmune and antibody profiles, its long course and tendency for spontaneous cure makes the design of clinical trials difficult. The overwhelming need in this disease is to diagnose it early and identify those patients who will benefit most from early, aggressive treatment. We attempt to review data from recent clinical trials and the lessons derived.
Keywords: New drugs, Scleroderma, Trials
|How to cite this article:|
Sardana K, Garg V K. Therapeutic trials for systemic sclerosis: An update. Indian J Dermatol Venereol Leprol 2008;74:436-46
|How to cite this URL:|
Sardana K, Garg V K. Therapeutic trials for systemic sclerosis: An update. Indian J Dermatol Venereol Leprol [serial online] 2008 [cited 2020 Jan 19];74:436-46. Available from: http://www.ijdvl.com/text.asp?2008/74/5/436/44298
| Definition|| |
Scleroderma is derived from the Greek words skleros (hard or indurated) and derma (skin). It was initially defined by Hippocrates, but a detailed description was given by Carlo Curzio. 
| Pathogenesis|| |
It is an autoimmune disorder that involves interaction of three pathogenetic factors: vasculopathy of small arteries and capillaries, fibrosis, and immunologic damage.
Systemic sclerosis (SSc) is characterized by tissue fibrosis, obliterative microangiopathy, and immune abnormalities  .
The role of autoimmunity in generating the clinical and pathologic phenotype in SSc remains uncertain. , The process starts with microvascular change and endothelial cell activation, which is followed by inflammation and immune cell activation, with a perivascular infiltration of inflammatory cells initially from the innate immune system and including cells of the monocyte/macrophage lineage. , Later, there is evidence of involvement of the adaptive immune system.  Lymphocytic infiltrates are noted, including T cells bearing markers of activation. ,, Recent studies have also identified B-cell genetic signature.,
As the disease progresses, there is evidence of a profibrotic fibroblastic cell population becoming established within the skin. , This leads to increased extracellular matrix deposition. ,, As the disease becomes well established, lesional skin becomes relatively avascular; and after 12 to 18 months, there is often little evidence of ongoing inflammation. This suggests that there are probably distinct phases, at least in the skin, when the component processes of SSc might be amenable to therapeutic modulation. , The production of various cytokines consequent to vessel damage, intimal hyperplasia, and platelet aggregation lead to contraction of the vessels, which causes obliterative microangiopathy , .
Thus, targeted therapy is likely to depend critically on the disease stage and subset.
There is a complex interaction between multiple cell types during the evolution of SSc. ,, These cell types may interact through direct contact, but soluble mediators are also likely to be critical. , These regulate cell migration, differentiation, and proliferation. Cellular origins may be diverse within lesional tissue, and there has been a recent focus on the role of progenitor cells locally or migrating from other sites, such as bone marrow or from peripheral blood. ,, The myofibroblast is the effector cell for fibrosis and many other organ-based changes. , Myofibroblasts are likely to be derived from at least three sources: local fibroblasts, transdifferentiation, and other cell types. , Circulating and locally produced soluble mediators regulate this process. , The key patterns of intercellular interaction that operate in SSc pathogenesis are summarized. ,
Treatment of systemic sclerosis has been somewhat haphazard, and treatment has often been 'borrowed' from the experience gained from treating other connective tissue diseases. , There was a period of time that was focused mainly on organ-specific manifestations of systemic sclerosis, and some advance in preventing vital-organ damage (such as renal crisis) was achieved.
At present, there are no treatments that are known to change the overall course of SSc. ,
Survival has improved dramatically in recent years and is due to the effectiveness of treatments directed at specific internal organ features. These include drugs for pulmonary hypertension (epoprostenol, treprostinil, bosentan); renal involvement (angiotensin-converting enzyme inhibitors); and pulmonary inflammation (cyclophosphamide). ,,
Clinical research on therapies for scleroderma is currently very active. The choice of therapy is complex and depends on the type of SSc (diffuse versus limited); the stage of illness (early versus late); and the specific organ-related problems faced by the individual patient. ,,,
The future and present trials would focus on the cellular mediators in systemic sclerosis as potential therapeutic targets  [Table 1].
Our focus will be on the potentially positive, negative, and open enrollment trials in SSc.
| Trials Completed: Potentially Positive Results|| |
Bosentan [Table 2]
Bosentan is the first orally active, high-affinity endothelin dual receptor antagonist approved for the treatment of pulmonary arterial hypertension. ,,, Elevated circulating levels and increased tissue expression of endothelin-1 are characteristic of SSc, and patients demonstrate endothelin receptor overexpression in affected tissues and organs. ,,
Two randomized trials have demonstrated that bosentan is effective in idiopathic pulmonary arterial hypertension and in pulmonary arterial hypertension related to connective tissue diseases. ,
Oral bosentan 125 mg twice daily in improving exercise capacity has been demonstrated in well-designed trials in adult patients with idiopathic pulmonary arterial hypertensions (PAH) or PAH associated with connective tissue disease or congenital systemic-to-pulmonary shunts, and in other trials in patients with idiopathic PAH or PAH associated with congenital heart disease or HIV infection. , The beneficial effects of bosentan treatment may be maintained for up to 1 year in patients with idiopathic PAH or PAH associated with connective tissue disease. 
Despite the potential for treatment-related teratogenicity and hepatotoxicity, long-term data indicate that bosentan is generally well tolerated at the approved dosages. 
Although well-designed trials are required to establish the efficacy of bosentan versus, or in combination with, other specific PAH therapies, especially sildenafil, the convenient oral administration and lack of serious injection-related adverse effects may render bosentan preferable to other PAH therapies.  Preliminary data indicate that bosentan may be effective in pediatric PAH patients, although randomized trials are required. 
The tolerability of bosentan is good in SSc patients.  The post-marketing surveillance program demonstrated that elevated liver enzymes after treatment initiation were recorded in 9.4% of the 1070 SSc patients treated with bosentan by November 19, 2004, compared with 8.4% in idiopathic pulmonary arterial hypertension patients. 
For digital ulcers in SSc, two randomized clinical trials supported the efficacy of bosentan for the prevention of new digital ulcers (up to almost 50% less new digital ulcers). ,, The treatment effect appeared more pronounced in the most severe cases (patients with three or more digital ulcers at baseline). , However, bosentan did not demonstrate beneficial effect on SSc interstitial lung disease after 1 year of treatment in a randomized, controlled study. , Whether a subgroup of SSc patients with interstitial lung disease benefits from bosentan requires further investigation. Another randomized, controlled study performed in idiopathic pulmonary fibrosis has demonstrated a treatment effect on time to disease progression or death in the subgroup with biopsy-proven idiopathic pulmonary fibrosis. ,
Halofuginone has been used to treat fibrosis in chronic graft-versus-host disease and scleroderma. , Chronic graft-versus-host disease (cGvHD) and systemic sclerosis share clinical characteristics, including skin and internal organ fibrosis.  Fibrosis, regardless of the cause, is characterized by extracellular matrix deposition, of which collagen type I is the major constituent. ,, The progressive accumulation of connective tissue results in destruction of normal tissue architecture and internal organ failure.  In both SSc and cGvHD, the severity of skin and internal organ fibrosis correlates with the clinical course of the disease. 
Halofuginone is an inhibitor of collagen type I synthesis in cells derived from various tissues and species and in animal models of fibrosis in which excess collagen is the hallmark of the disease. , Halofuginone decreased collagen synthesis in the tight skin mouse (Tsk) and murine cGvHD, the two experimental systems that show many features resembling those of human GvHD.  As a first step toward future treatment of internal organ involvement, an oral administration study was performed in which halofuginone was well tolerated and plasma levels surpassed the predicted therapeutic exposure. 
Patients received infliximab 5 mg/kg at weeks 0, 2, 6, 14, 22. The primary efficacy objective was to assess the change from baseline to week 26 using the modified Rodnan skin score (mRSS), SSc functional score (FS), and physician global assessment on visual analog scale (VAS). , A key secondary objective of the study was to assess safety and tolerability of infliximab in diffuse cutaneous systemic sclerosis (dcSSc). Infliximab appears to provide cutaneous disease stability and there may be short-term improvement in skin sclerosis, although significant benefit at 6 months was not demonstrated. ,
A double-blind placebo-controlled trial was performed in 56 patients with systemic sclerosis effectiveness of a domestic drug ximedon - a pyrimidine compound - applied during electrophoresis on the affected skin, limbs.  The addition of ximedon-electrophoresis to the rehabilitation program for systemic sclerosis patients improved the condition in 77.8%, microhemo-circulation in 72.2%; and reduced the area of the affected skin by 9.8% ( P < 0.05), skin induration in 55.6% of the patients. 
Intravenous immunoglobulin (IVIg)
Intravenous immunoglobulin (IVIg) is used to treat a number of immune-deficiencies and autoimmune diseases. , It has been shown that IVIg contains anti-idiotypic antibodies, which explains its immunomodulatory action. In murine models, recent investigations have demonstrated that IVIg can prevent, and reduce the affliction by systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), and SSc. ,
A study suggested that intravenous immunoglobulins may reduce joint pain and tenderness, with a significant recovery of joint function in patients with SSc with severe and refractory joint involvement. With high-dose intravenous immunoglobulin (IVIg) at a dose of 400 mg/kg daily for 5 consecutive days, Total scleroderma score of the patient improved dramatically up to 4 weeks after IVIg (from 22 to 17 at 2 weeks and 14 at 4 weeks), and then gradually improved over 2 years (from 14 to 7).  The cost of intravenous immunoglobulins might limit their use only to patients who failed disease-modifying antirheumatic drugs. 
A study on methotrexate (15 mg/week) for 6 months showed that it only provides subjective improvement.  A recent placebo-controlled trial of methotrexate in systemic sclerosis showed that clinical improvement following treatment was observed in 33.33% of the patients in the MTX group but none in the placebo group, but this difference was not statistically significant.  Thus pending further studies, its role has not been conclusively proved.
A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis showed that photopheresis induced significant improvement with regard to skin and joint involvement in patients with scleroderma of recent onset; however, any effect when compared with sham treatment and a possible placebo effect may be modest.
PUVA/UVA-1 and phototherapy 
Though clinically significant effects have not been seen in systemic sclerosis, a study of low-dose UVA1, medium-dose UVA1, and narrow-band UVB phototherapy in the treatment of localized scleroderma (LS) gives hope for the cutaneous aspects of the disease.
A total of 27 patients were treated with LD (low-dose) UVA1 (20 J/cm 2 ), 18 patients received MD (medium-dose) UVA1 (50 J/cm 2 ), and 19 patients were treated with narrow -band ultraviolet B light (NB-UVB), dependent on their skin type. Phototherapy was performed 5 times weekly for 8 weeks. The reduction of the score was accompanied by an improvement of the visual analog scale for itching and tightness, histologic score, and 20-MHz ultrasound. MD UVA1 was significantly more effective than NB UVB ( P < 0.05).
Even though holding the risk of carcinogenesis, photoaging, or UV-induced exacerbation, UVA phototherapy seems to exhibit a tolerable risk/benefit ratio, at least in systemic sclerosis, localized scleroderma, extragenital lichen sclerosus et atrophicus, sclerodermoid graft-versus-host disease, lupus erythematosus, and a number of sclerotic rarities.  This modality works by ,, various potential pathways, including immunomodulation of inflammation, induction of collagenases, and initiation of apoptosis.
(Potential therapeutic agent derived from, deglycolipidated Mycobacterium vaccae )
Use of PVAC in this pilot study of PSS appeared safe and was associated with a trend towards improved skin scores and other efficacy outcomes in the treatment group. Patients were of diffuse scleroderma and received 8 intradermal injections of 15 µg PVAC or placebo at 3-week intervals. The primary efficacy endpoint was the change in modified Rodnan skin score (mRSS) at week 24. Use of PVAC in patients with SSc appeared safe and was associated with a trend towards improved skin scores in the 15 microg treatment group
Urokinase therapy 
Gradual clinical improvement was observed with urokinase therapy, as evidenced by a noticeable restoration of skin elasticity and softness. Moreover, patients reported less intense symptoms of Raynaud's phenomenon and improvements in articular range, including previously limited movements. The authors concluded that 'therapy with urokinase seems to be a rational treatment in this disease' as it appears to 'modify the course and evolution of systemic sclerosis'.
| Current Studies, Open Enrollments|| |
Allogeneic hematopoietic stem cell transplantation (NST) for patients with systemic sclerosis. ,,,
This study is designed to examine whether treating patients with high-dose cyclophosphamide and fludarabine (drugs which reduce the function of the immune system) and CAMPATH-1H (a protein that kills the immune cells that are thought to be causing the disease), followed by return of blood stem cells that have been previously collected from the patient's brother or sister, will stop or reverse the disease.
ASTIS study 
High-dose immunoablation and hematopoietic stem cell transplantation versus monthly intravenous pulse therapy with cyclophosphomide in severe systemic sclerosis
This is a multicenter, prospective, controlled, randomized, phase III study comparing high-dose immunoablation and autologous hematopoietic stem cell transplantation with monthly pulse therapy with cyclophosphomide in patients with severe systemic sclerosis.
The European Group for Blood and Marrow Transplantation/ European League Against Rheumatism reported an analysis of their database of 57 patients with SSc treated by hematopoietic stem cell transplantation, with more than 6 months of follow-up. It revealed that the response in two thirds of the patients after hematopoietic stem cell transplantation was durable, with an acceptable transplant-related mortality of 8.7%. 
(cyclophosphamide [50 mg/kg] intravenously daily for 4 consecutive days [total 200 mg/kg])
A placebo-controlled trial revealed that 1 year of oral cyclophosphamide in patients with symptomatic scleroderma-related interstitial lung disease had a significant but modest beneficial effect on lung function, dyspnea, thickening of the skin, and the health-related quality of life. The effects on lung function were maintained through the 24 months of the study. 
A further study revealed that after adjusting for the severity of fibrosis at baseline, CYC slowed the decline of lung volumes and improved dyspnea equally in the limited and the diffuse SSc groups. On the other hand, diffuse SSc patients responded better than limited patients with respect to improvements in skin thickening.  Though the results of cyclophosphamide therapy in improving lung function, skin scores, dyspnea, and health status-disability are established, except for a sustained impact on dyspnea, all of these effects waned and were no longer apparent at 24 months. Treatment strategies aimed at extending the positive therapeutic effects observed with cyclophosphamide should be considered. 
A potential combination, used with variation in India, is a combination with methyl prednisolone. 
(Up to 80 mg/day in patients with limited cutaneous systemic sclerosis (lcSSc) for 3 years)
A multicentric trial, called the QUINS trial, has been initiated that includes, amongst other drugs, quinapril in scleroderma, which holds promise to replace the existing ACE inhibitor drugs in PSS.
This appears to be beneficial for a variety of scleroderma symptoms, such as digital ulcers, pulmonary fibrosis, pulmonary hypertension, and skin fibrosis, as previously discussed.
SCOT clinical trial 
This is an ongoing trial which stands for 'scleroderma - cyclophosphamide or transplantation'; it will compare two potential therapies: autologous stem cell transplantation versus high-dose monthly cyclophosphamide.
Sildenafil , [Table 1]
Nitric oxide is an important mediator that has proinflammatory effects at high levels and is an important mediator of endothelium-dependent vasodilatation. The effects of nitric oxide are mediated via cGMP, and levels of this second messenger are increased when the degradative enzyme phosphodiesterase V is inhibited. This mechanism underlies the beneficial effect of agents such as sildenafil in the treatment of PAH complicating SSc.
Imatinib mesylate , [Table 1]
Pericytes may be important in the development of fibrosis by transdifferentiation into fibroblasts or myofibroblasts. This process may be intrinsic to wound healing and is regulated by platelet-derived growth factor. Its importance in organ-based fibrosis is unclear; but in the skin, recent studies have clearly shown that platelet-derived growth factor (PDGF) signaling is critical to pericyte activation and that this sequence occurs as SSc progresses. Imatinib also inhibits the activation of c-Abl, which is a key downstream molecule of transforming growth factor-beta signaling, and PDGF receptors.
Thus, imatinib effectively suppresses the activation and proliferation of fibroblasts, mesangial cells, and smooth muscle cells. Therefore, imatinib may overcome the limitation of current therapeutic strategy with corticosteroids and immunosuppressive agents for refractory diseases.
| Trials Completed: Awaiting Results|| |
These include various studies which have finished but the results are formally awaited. They include oral type 1 collagen in scleroderma, persistent infection in systemic sclerosis, and psychological treatments for scleroderma.
Also, studies with some molecules like DMSO (dimethyl sulfoxide)  have been found to be inconclusive.
| Trials Completed: Negative Results|| |
The following treatments are either ineffective or unproven for the treatment of scleroderma. These range from the new molecules like anti-TGF-beta monoclonal antibodies (CAT 192), relaxin,, and the older drugs like azathioprine,  chlorambucil,  gamma interferon,  minocycline, penicillamine, potaba  and tamoxifen. 
A conclusive study on this drug compared 822 mg daily versus low-dose 120 mg every other day. The study revealed that there was no statistical difference between either dose and the drug is no better than a placebo. But interest has been rekindled by a recent study  that retrospectively randomly selected 84 patients with diffuse cutaneous systemic sclerosis who had received D-penicillamine within 24 months of clinically detectable onset of skin sclerosis. At a median dose of 750 mg per day, statistically significant improvement with regard to skin, cardiac, pulmonary, and renal involvement was observed. The study concluded that in cases with diffuse cutaneous systemic sclerosis, with progressive disease of recent onset, D-penicillamine treatment at a median dose of 750 mg per day can cause a significant reduction in skin involvement and improvement with regard to renal, cardiac, and pulmonary functioning.
But as most of the literature on the drug is inconclusive ,,,, or has negative  results, the drug's role is still kept in this category.
| The Future|| |
Most of the latest research is now focused on pulmonary arterial hypertension (PAH), which is an important cause of death in systemic sclerosis (SSc), despite the improvement in therapies. ,,,,
Lately, new specific therapies have been developed targeting prostacyclin, endothelin, and nitric oxide pathways, the major pathogenic pathways leading to endothelial dysfunction in PAH. ,,
Epoprostenol improved life expectancy of patients with primary and secondary PAH. More stable analogues of prostacyclin, administrated by intravenous (iloprost, treprostinil), subcutaneous, inhalatory (treprostinil, iloprost), and oral route (Beraprost), have shown efficacy in PAH. ,,,
Bosentan, the first oral endothelin receptor antagonist (with affinity for endothelin A and B receptors), improves exercise function and survival in PAH, both primary and secondary to autoimmune rheumatic diseases. ,,,,,, This is confirmed by new drugs like sitaxsentan and ambrisentan, selective endothelin A receptor antagonists. ,,
Inhibitors of NO degradation, such as sildenafil, a phosphodiesterase (PDE) type 5 inhibitor, improved functional and hemodynamic parameters without significant side effects. ,,, Vardenafil and taladafil, longer-acting PDE inhibitors, also have vascular pulmonary selectivity. ,,
All these drugs may be used in combination, to maximize their clinical benefit not only in patients unresponsive to single drugs but also potentially as initial therapy for PAH.
A recent review describes the role of natural therapies in scleroderma. It reviews several promising natural treatments for scleroderma, including para-aminobenzoic acid, vitamin E, vitamin D, evening primrose oil, estriol, N-acetylcysteine, bromelain, and an avocado/soybean extract. 
Most pharmacotherapeutic interventions to treat the disease remain empiric. Efforts to document efficacy have been disappointing when therapies are tested in controlled trials. ,,,,,,,,,, Many of these trials were doomed to fail, given the heterogeneous nature of disease expression; and too often, patients had late disease with established fibrosis that would not necessarily be amenable to the treatments tried. Clinical trials are characterized by their ability to answer very specific, straightforward questions in a well-defined relatively homogeneous patient population. Although this can provide important answers, it may not be representative of complex real-life scenarios. Other problems are that the patient populations tend to be highly selective, long-term outcome studies are notoriously difficult to perform, it is difficult to enroll adequate patient numbers, the disease is extremely slow to progress, and spontaneous improvement is observed in many. This makes it difficult to show benefits of therapy over placebo. As a result, meaningful results are more likely to be obtained by identifying and targeting patients who are most likely to progress, rather than those who remain stable over the course of a clinical trial.
The optimal way to achieve this is a matter of much debate; and till then, therapy will largely depend on symptomatic relief ,, hoping for the natural course of disease to supervene and lend a hand to the existing therapeutic regimens ,,,,,,,,,, [Table 3],[Table 4],[Figure 1].
The best "disease modifying therapy "at present seem to be immunosuppressive drugs [Figure 1].
| Acknowledgment|| |
We acknowledge the help taken from the site ClinicalTrials.org, BioMed Central, and the Creative Commons Attribution License to use.
| References|| |
|1.||Sapadin AN, Fleischmajer R. Treatment of scleroderma. Arch Dermatol 2002;138:99-105. [PUBMED] [FULLTEXT]|
|2.||Denton PC. Therapeutic targets in systemic sclerosis. Arthritis Res Ther 2007;9:S6. |
|3.||Rubin LJ, Black CM, Denton CP, Seibold JR. New therapeutic strategies for systemic sclerosis: A critical analysis of the literature. Clin Dev Immunol 2005;12:165-73. |
|4.||Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006;367:1683-91. [PUBMED] [FULLTEXT]|
|5.||Matucci-Cerinic M, Steen VD, Furst DE, Seibold JR. Clinical trials in systemic sclerosis: lessons learned and outcomes. Arthritis Res Ther 2007;9:S7. [PUBMED] [FULLTEXT]|
|6.||Hachulla E, Launay D, Humbert M. Bosentan for the treatment of scleroderma. Future Rheumatol 2006;1:549-62. |
|7.||Ahmadi-Simab K, Hellmich B, Gross WL. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease. Eur J Clin Invest 2006;36:44-8. [PUBMED] [FULLTEXT]|
|8.||Pines M, Snyder D, Yarkoni S, Nagler A. Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol Blood Marrow Transplant 2003;9:417-25. [PUBMED] [FULLTEXT]|
|9.||Salikhov IG, Bodrova RA, Ziganshina LE. Ximedon-electrophoresis in rehabilitation of patients with systemic scleroderma. Vopr Kurortol Fizioter Lech Fiz Kult 2002;5:33-6. [PUBMED] |
|10.||Asano Y, Ihn H, Asashima N, Yazawa N, Mimura Y, Jinnin M, et al . A case of diffuse scleroderma successfully treated with high-dose intravenous immune globulin infusion. Rheumatology (Oxford) 2005;44:824-6. [PUBMED] [FULLTEXT]|
|11.||Nacci F, Righi A, Conforti ML, Miniati I, Fiori G, Martinovic D, et al . Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: A pilot study. Ann Rheum Dis 2007;66:977-9. [PUBMED] [FULLTEXT]|
|12.||Krishna Sumanth M, Sharma VK, Khaitan BK, Kapoor A, Tejasvi T. Evaluation of oral methotrexate in the treatment of systemic sclerosis. Int J Dermatol 2007;46:218-23. [PUBMED] [FULLTEXT]|
|13.||Knobler RM, French LE, Kim Y, Bisaccia E, Graninger W, Nahavandi H, et al . A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis. J Am Acad Dermatol 2007;56:348-9. |
|14.||Kreuter A, Hyun J, Stücker M, Sommer A, Altmeyer P, Gambichler T. A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol 2006;54:440-7. |
|15.||Breuckmann F, Gambichler T, Altmeyer P, Kreuter A. UVA/UVA1 phototherapy and PUVA photochemotherapy in connective tissue diseases and related disorders: A research based review. BMC Dermatol 2004;1:11. |
|16.||Bazzichi L, Rossi A, De Giorgio F, Gesi M, Lenzi P, Pellegrini A. Clinical improvement in systemic sclerosis resulting from urokinase therapy explained by light and electron microscopy skin examination. Scand J Rheumatol 2003;32:261. [PUBMED] |
|17.||Farge D, Passweg J, van Laar JM, Marjanovic Z, Besenthal C, Finke J, et al . Autologous stem cell transplantation in the treatment of systemic sclerosis: An extended report from the EBMT/EULAR Registry. Ann Rheum Dis 2004;63:974-81. [PUBMED] [FULLTEXT]|
|18.||Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655-66. |
|19.||Clements PJ, Roth MD, Elashoff R, Tashkin DP, Goldin J, Silver RM, et al . Scleroderma lung study (SLS): Differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis 2007;66:1641-7. [PUBMED] [FULLTEXT]|
|20.||Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, Goldin J, et al . Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007;176:1026-34. [PUBMED] [FULLTEXT]|
|21.||Yiannopoulos G, Pastromas V, Antonopoulos, Katsiberis G, Kalliolias G, Liossis SN, et al . Combination of intravenous pulses of cyclophosphamide and methylprednizolone in patients with systemic sclerosis and interstitial lung disease. Rheumatol Int 2007;27:357-61. |
|22.||Maddison P. Prevention of vascular damage in scleroderma with angiotensin-converting enzyme (ACE) inhibition. Rheumatology (Oxford) 2002;41:965-71. [PUBMED] [FULLTEXT]|
|23.||Sener RĂ, Ăbben R. Treatment of a leg ulcer with bosentan in a female patient with progressive systemic scleroderma. Hautarzt 2007;58:392-3. |
|24.||Yu EP, Ostor AJ, Hall FC. Successful treatment with bosentan for severe digital ischaemia in limited cutaneous systemic sclerosis. Ann Rheum Dis 2007;66:1122-3. [PUBMED] [FULLTEXT]|
|25.||Hettema ME, Zhang D, Bootsma H, Kallenberg CG. Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis. Ann Rheum Dis 2007;66:1398-9. [PUBMED] [FULLTEXT]|
|26.||Csuka ME. High dose immunosuppressive therapy and autologous hematopoietic stem cell transplantation for treatment of severe systemic sclerosis. Scleroderma Care Res 2005;3:3-11. |
|27.||Fries R, Shariat K, von Wilmowsky H, Bohm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 2005;112:2980-5. |
|28.||Kameda H. Imatinib mesylate as a novel therapeutic drug for systemic rheumatic diseases. Nihon Rinsho Meneki Gakkai Kaishi 2007;30:165-73. [PUBMED] [FULLTEXT]|
|29.||Trice JM, Pinals RS. Dimethyl sulfoxide: A review of its use in the rheumatic disorders. Semin Arthritis Rheum 1985;15:45-60. [PUBMED] [FULLTEXT]|
|30.||Varga J, Korn JH. Pathogenesis: Emphasis on human data. In: Clements P, Furst D, editors. Systemic Sclerosis. Philadelphia, Pa: Lippincott Williams and Wilkins; 2004. p. 63-97. |
|31.||Mayes MD, O'Donnell D, Rothfield NF, Csuka ME. Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial. Arthritis Rheum 2004;50:553-7. [PUBMED] [FULLTEXT]|
|32.||Clements PJ, Seibold JR, Furst DE, Mayes M, White B, Wigley F, et al . High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: Lessons learned. Semin Arthritis Rheum 2004;33:249-63. [PUBMED] [FULLTEXT]|
|33.||Derk CT, Huaman G, Jimenez SA. A retrospective randomly selected cohort study of D-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset. Br J Dermatol 2008;158:1063-8. [PUBMED] [FULLTEXT]|
|34.||Clegg DO, Reading JC, Mayes MD, Seibold JR, Harris C, Wigley FM, et al . Comparison of aminobenzoate potassium and placebo in the treatment of scleroderma. J Rheumatol 1994;21:105-10. [PUBMED] |
|35.||Thomas-Golbanov CK, Wilke WS, Fessler BJ, Hoffman GS. Open label trial of tamoxifen in scleroderma. Clin Exp Rheumatol 2003;21:99-102. [PUBMED] |
|36.||Cerinic Matucci M, Del Rosso A, Federico P, Livi R, Fiori G, Bartoli F, et al . Therapeutic challenges for systemic sclerosis: Facts and future targets. Ann N Y Acad Sci 2007;1110:448-54. [PUBMED] [FULLTEXT]|
|37.||Gaby AR. Natural remedies for scleroderma. Altern Med Rev 2006;11:188-95. [PUBMED] [FULLTEXT]|
|38.||Furst DE, Clements PJ, Harris R, Ross M, Levy J, Paulus HE. Measurement of clinical change in progressive systemic sclerosis: A 1year double-blind placebo-controlled trial of N-acetylcysteine. Ann Rheum Dis 1979;38:356-61. [PUBMED] [FULLTEXT]|
|39.||Blom-Bulow B, Oberg K, Wolheim FA, Persson B, Jonson B, Malmberg P, et al . Cyclofenil versus placebo in progressive systemic sclerosis: A one-year double-blind crossover study of 27 patients. Acta Med Scand 1981;210:419-28. |
|40.||Beckett VL, Conn DL, Fuster V, Osmundson PJ, Strong CG, Chao EY, et al . Trial of platelet inhibition drug in scleroderma: Double-blind study with dipyridamole and aspirin. Arthritis Rheum 1984;27:1137-43. [PUBMED] |
|41.||Williams HJ, Furst DE, Dahl SL, Steen VD, Marks C, Alpert EJ, et al . Double-blind, multicenter controlled trial comparing topical dimethyl sulfoxide and normal saline for treatment of hand ulcers in patients with systemic sclerosis. Arthritis Rheum 1985;28:308-14. [PUBMED] |
|42.||Furst De, Clements PJ, Hillis S, Lachenbruch PA, Miller BL, Sterz MG, et al . Immunosuppression with chlorambucil, versus placebo, for scleroderma: Results of a three-year, parallel, randomized, double-blind study. Arthritis Rheum 1989;32:584-93. [PUBMED] |
|43.||O'Dell JR, Steigerwald JC, Kennaugh RC, Hawkins R, Holers VM, Kotzin BL. Lack of clinical benefit after treatment of systemic sclerosis with total lymphoid irradiation. J Rheumatol 1989;16:1050-4. [PUBMED] |
|44.||Casas JA, Saway PA, Villarreal I, Nolte C, Menajovsky BL, Escudero EE, et al . 5-fluorouracil in the treatment of scleroderma: A randomized, double blind, placebo controlled international collaborative study. Ann Rheum Dis 1990;49:926-8. [PUBMED] [FULLTEXT]|
|45.||Gruber BL, Kaufman LD. A double-blind randomized controlled trial of ketotifen versus placebo in early diffuse scleroderma. Arthritis Rheum 1991;34:362-6. [PUBMED] |
|46.||van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: A 24-weel randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996;35:364-72. |
|47.||Black CM, Silman AJ, Herrick AI, Denton CP, Wilson H, Newman J, et al . Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1999;42:299-305. [PUBMED] [FULLTEXT]|
|48.||Seibold JR, Korn JH, Simms R, Clements PJ, Moreland LW, Mayes MD, et al . Recombinant human relaxin in the treatment of scleroderma: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000;132:871-9. [PUBMED] [FULLTEXT]|
|49.||Scleroderma. In: DuPont H, Gardner LB, et al , editors. Kelley's Textbook of Internal Medicine. 4th ed. Lippincott Williams and Wilkins; 2000. |
|50.||Scleroderma. In: Frank AK, Frank MM, Atkinson JP, editors. Samter's immunologic diseases. 6th ed. Lavoisier; 2000-2008. |
|51.||Scleroderma. Rheumatology. In: Dale DC, Federman DD, editors. ACP medicine. Web MD; 2006 (incomplete). |
|52.||Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, et al . A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54:3962-70. [PUBMED] [FULLTEXT]|
|53.||Vanthuyne M, Blockmans D, Westhovens R, Roufosse F, Cogan E, Coche E, et al . A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol 2007;25:287-92. [PUBMED] [FULLTEXT]|
|54.||Gilliland BC. Systemic sclerosis (scleroderma) and related disorders. In: Kasper DI, Braunwald E, Fauci AS, Hauser SI, editors. Harrison's principles of internal medicine. 16th ed. New York: McGraw-Hill; 2005. p. 1979-99. |
|55.||Nihtyanova SI, Denton CP. Current approaches to the management of early active diffuse scleroderma skin disease. Rheum Dis Clin North Am 2008;34:161-79. [PUBMED] [FULLTEXT]|
|56.||Herrick A. Diagnosis and management of scleroderma peripheral vascular disease. Rheum Dis Clin North Am 2008;34:89-114. [PUBMED] [FULLTEXT]|
|57.||Rubin LJ. Treatment of pulmonary arterial hypertension due to scleroderma: Challenges for the future. Rheum Dis Clin North Am 2008;34:191-7. [PUBMED] [FULLTEXT]|
|58.||Distler J, Distler O. Novel treatment approaches to fibrosis in scleroderma. Rheum Dis Clin North Am 2008;34:145-59. [PUBMED] [FULLTEXT]|
|59.||Pasricha JS, Ramam M, Shah S. Reversal of systemic sclerosis with dexamethasone pulses. Indian J Dermatol Venereol Leprol 1990;56:40-2. |
|60.||Saoji VA. Premature ovarian failure due to cyclophosphamide: A report of four cases in dermatology practice. Indian J Dermatol Venereol Leprol 2008;74:128-32. [PUBMED] |
|61.||Ahmad QM, Shah IH, Nauman Q, Farah S, Javaid S. Increased incidence of tuberculosis in patients of systemic sclerosis on dexamethasone pulse therapy: A short communication from Kashmir. Indian J Dermatol 2008;53:24-5. |
|62.||Scleroderma and related disorders in adults and children. In: Isenberg DA, Maddison, PJ, Woo P, Glass D, Breedveld FC, editors. Oxford textbook of rheumatology. 3rd ed. Section 6. Subsection 76.7. Oxford University Press; 2004. |
[Table 1], [Table 2], [Table 3], [Table 4]
|This article has been cited by|
||Dexamethasome-cyclophosphamide pulse therapy for systemic sclerosis
| ||Gupta, R. |
| ||Indian Journal of Dermatology, Venereology and Leprology. 2009; 75(5): 511 |
||Systemic sclerosis and dexamethasone cyclophosphamide pulse therapy
| ||Pasricha, J.S. |
| ||Indian Journal of Dermatology, Venereology and Leprology. 2009; 75(5): 510-511 |
| ||Sardana, K., Garg, V. |
| ||Indian Journal of Dermatology, Venereology and Leprology. 2009; 75(5): 511-513 |